SchizophreniaCBTSZNCT03316664
Assessment of Efficacy of a Psychological Therapy in Inpatients With a Schizophrenic Psychosis
A study testing Integrated Neurocognitive Therapy (INT), Integrated Psychological Therapy (IPT) and COGPACK in people with Schizophrenia and Schizoaffective Disorder, run by Psychiatric University Hospital, Zurich at 1 site in Switzerland.
Trial summary
This randomised three-arm study aims to evaluate the efficacy and feasibility of a cognitive behavioral therapy (INT-Integrated Neurocognitive Therapy for Schizophrenia Patients) in the treatment of schizophrenia patients in an inpatient setting. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
- What is being tested?
- Integrated Neurocognitive Therapy (INT), Integrated Psychological Therapy (IPT) and COGPACK
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 82 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jun 2018to 31 Aug 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants are competent to give informed consent.
- Diagnosis of Schizophrenia or Schizoaffective Disorder (ICD-10).
- Participants are between 18 and 65 years of age.
- Fulfillment of regular compulsory education.
- German language proficiency as a native speaker or level B1
Who cannot join
- Unwilling or unable to comply with study instructions.
- Low Intelligence as stated by failure to accomplish regular compulsory education.
- Currently in another psychotherapeutic treatment, either in individual or group sessions.
- Current consumption of Alcohol or illicit Drugs.
Trial locations and contacts
1 site in 1 country.
About this study
This randomised three-arm study aims to evaluate the efficacy and feasibility of a cognitive behavioral therapy (INT-Integrated Neurocognitive Therapy for Schizophrenia Patients) in the treatment of schizophrenia patients in an inpatient setting. The intervention will be compared with an active comparator (IPT- Integrated Psychological Therapy) and a control condition. Overall the study will include 90 patients (30 in each arm). Each patient will receive at least 16 sessions of the respective treatment. Baseline and follow up assessments up to 12 months after the intervention will investigate the stability of treatment.
Read the detailed description
Psychotic disorders, and particularly schizophrenia, are severe psychiatric disorders, characterized by psychotic symptoms (mainly hallucinations and delusions), disorganized speech, thought and behavior, and negative symptoms like blunted affect. People who have schizophrenia are chronically impaired. Schizophrenia is one of the first causes of disability worldwide with enormous direct and indirect costs.
The introduction of antipsychotics revolutionized the treatment and care of schizophrenia patients; remaining the cornerstone of schizophrenia treatment. Although new antipsychotics were introduced, they share the same mechanism of action (dopamine D2 antagonism). To date, nearly one-third to half of the patients still do not or respond poorly to antipsychotic treatment; furthermore, some core symptoms of the disorder are not fully addressed by this type of medication.
Parallel to pharmacological treatments, there has been a steady research in psychological interventions for schizophrenia. Current interventions had a more biologic understanding of the disorder and adopted a diathesis-stress model to explain symptoms and course, incorporating adaptation and adjustment through learned and practiced coping strategies. There are many psychological treatments for schizophrenia, although all are considered roughly equivalent, empirical data shows slight differences in efficacy; in particular, Cognitive Behavioural Therapy (CBT) yields small to medium sized effects in addition to psychopharmacological treatment.
There are several available manualized psychological group interventions for patients with a schizophrenic psychosis. One the is the "Integrated Psychological Therapy for Schizophrenia Patients (IPT)", it was developed and introduced into clinical practice almost 30 years ago. It combines neurocognitive and social cognitive interventions with social skills and problem- solving approaches, it has been extensively evaluated by several independent groups, in inpatient and outpatient settings as well, showing an overall improvement in participants.
During the last decade, the cognitive section of IPT was further developed, with the "Integrated Neurocognitive Therapy for schizophrenia patients (INT)" was the final result of this process, with the peculiarity that it was designed to fit the needs of outpatients. While IPT focuses predominantly on the domains of speed of processing, attention, reasoning, and problem-solving as well as on emotion and social perception; INT in contrast targets all 11 neuro- and social-cognitive MATRICS-domains. Furthermore, INT uses computerized neurocognitive exercises for restitution. Initial trials seem to confirm INT as a feasible and efficient group therapy approach with the potential to improve functional outcome in schizophrenia outpatients
The investigators, plan investigational trial to assess the efficacy and feasibility of INT for patients with schizophrenia in an inpatient setting. Therefore, an 8-week, randomized, controlled, assessor-blind, three-parallel-arm trial is planned with patients diagnosed with a schizophrenic psychosis. Following baseline assessment, patients will be randomly assigned to either IPT, INT or a control intervention.
All study interventions, i.e.: the experimental intervention, the psychological control intervention, and the control condition will occur simultaneously twice a week to avoid participants from involuntarily switch groups. Therapists of the psychological experimental and control intervention, as well as trainers involved in the control condition, are not involved in the recruitment, assessment, and assignment of participants of the study. Study interventions will be held in group sessions with 6 to 8 participants each; we plan to conduct five such batches till we reach our sample size of at least 30 participants in each intervention arm.
Patients undergoing psychological interventions should have some prerequisites and conditions which make them suitable for the intervention; this, however, is not fully compatible with a random allocation of participants. Through randomization there is the possibility that participants are not able to cope with their assigned treatment; therefore in a pragmatic way patients will be allowed to switch in another treatment arm. Accordingly after two weeks; patients will be reassessed; reallocation will be followed according to predefined criteria for excessive demands or under requirement.
Participants which switch groups should complete the 8-week intervention in the second assigned group. The assessment at week two will be considered their baseline, with subsequent measures eight weeks later analog to those who did not switch treatment groups. For the final analysis and to preserve randomization the data from those who did not switch treatment groups will be analyzed: however data from the switching groups will be analyzed separately in an ITT fashion.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
- Being tested
- Integrated Neurocognitive Therapy (INT), Integrated Psychological Therapy (IPT), COGPACK
- Keywords
- cognitive behavioural therapy, psychotic disorder, schizophrenia, schizoaffective disorder, psychological intervention
- Medical subject headings
- Schizophrenia, Psychotic Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Integrated Neurocognitive Therapy (INT)Behavioural
Information already included in arm/group description.
Integrated Psychological Therapy (IPT)Behavioural
Information already included in arm/group description.
COGPACKOther
Information already included in arm/group description.
| Study group | Role | What they receive |
|---|---|---|
| INT | Experimental | Integrated Neurocognitive Therapy (INT) is a manualized psychological intervention that consists of 30 sessions administered by a therapist and a co-therapist in an open group of 6-8 patients. Sessions will take place twice a week, and each session should last 90 min. Receives: Behavioral: Integrated Neurocognitive Therapy (INT) |
| IPT | Active comparator | Integrated Psychological Therapy (IPT) is a manualized psychological intervention that consists of 5 modules which can be completed in a variable number of sessions that will be administered by a therapist and a co-therapist in an open group of 6- 8 patients. Sessions will take place twice a week, and each session should last 60 to 90 min. Receives: Behavioral: Integrated Psychological Therapy (IPT) |
| CoC | Other | COGPACK is a computer-based neuropsychological cognitive training program. It will be administered by a trainer in an open group of 6- 8 patients. Sessions will take place twice a week, and each session will last 45 - 60 minutes. Receives: Other: COGPACK |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline Symptomatology at 12 Months.
The "Positive and Negative Syndrome Scale" (PANSS) was designed to measure the severity of psychopathology in adult patients with a psychotic disorder, mainly schizophrenia and schizoaffective disorder.
Measured: Baseline, 2 Weeks, 10 Weeks, 6 Months, and 12 Months.
Secondary outcomes (1)
Change from Baseline Symptomatology at 12 Months.
The Mini-ICF (mICF) was developed to classify disorders according to the level of functioning and capacity in an abbreviated version.
Measured: Baseline, 2 Weeks, 10 Weeks, 6 Months, and 12 Months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2017
- Study start1 Jun 2018
- Primary completion31 Jul 2021
- Study completion31 Aug 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- An 8-week, randomized, controlled, assessor-blind, three-parallel-arm trial is planned with patients diagnosed with a schizophrenic psychosis.
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 82 participants (actual)
Sponsor and investigators
- Lead sponsor
- Psychiatric University Hospital, Zurich
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Stephan T. Egger, Psychiatric University Hospital, Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03316664
- Sponsor's protocol ID
- CBTSZ
- Acronym
- CBTSZ
- Status last verified
- Sep 2021
- First submitted
- 2 Oct 2017
- Last updated
- 16 Sep 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Redlich Bossy M, Mueller D, Seifritz E, Vetter S, Egger ST. Feasibility and Efficacy of a Psychological Therapy for Patients With a Schizophrenic Psychosis in an Inpatient Setting: Study Protocol of a Randomized Switch Controlled Trial. Front Public Health. 2020 Aug 12;8:391. doi: 10.3389/fpubh.2020.00391. eCollection 2020.
PubMed 32903368
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Efficacy of a Psychological Therapy in Inpatients With a Schizophrenic Psychosis
- ClinicalTrials.gov ID
- NCT03316664
- Acronym / sponsor ID
- CBTSZ / CBTSZ
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
- Keywords
- cognitive behavioural therapy, psychotic disorder, schizophrenia, schizoaffective disorder, psychological intervention
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 82 participants (actual)
- Lead sponsor
- Psychiatric University Hospital, ZurichUniversity, hospital or other
- Study start
- 1 Jun 2018 (actual)
- Primary completion
- 31 Jul 2021 (actual)
- Study completion
- 31 Aug 2021 (actual)
- First posted
- 20 Oct 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomised three-arm study aims to evaluate the efficacy and feasibility of a cognitive behavioral therapy (INT-Integrated Neurocognitive Therapy for Schizophrenia Patients) in the treatment of schizophrenia patients in an inpatient setting. The intervention will be compared with an active comparator (IPT- Integrated Psychological Therapy) and a control condition. Overall the study will include 90 patients (30 in each arm). Each patient will receive at least 16 sessions of the respective treatment. Baseline and follow up assessments up to 12 months after the intervention will investigate the stability of treatment.
Detailed description
Psychotic disorders, and particularly schizophrenia, are severe psychiatric disorders, characterized by psychotic symptoms (mainly hallucinations and delusions), disorganized speech, thought and behavior, and negative symptoms like blunted affect. People who have schizophrenia are chronically impaired. Schizophrenia is one of the first causes of disability worldwide with enormous direct and indirect costs.
The introduction of antipsychotics revolutionized the treatment and care of schizophrenia patients; remaining the cornerstone of schizophrenia treatment. Although new antipsychotics were introduced, they share the same mechanism of action (dopamine D2 antagonism). To date, nearly one-third to half of the patients still do not or respond poorly to antipsychotic treatment; furthermore, some core symptoms of the disorder are not fully addressed by this type of medication.
Parallel to pharmacological treatments, there has been a steady research in psychological interventions for schizophrenia. Current interventions had a more biologic understanding of the disorder and adopted a diathesis-stress model to explain symptoms and course, incorporating adaptation and adjustment through learned and practiced coping strategies. There are many psychological treatments for schizophrenia, although all are considered roughly equivalent, empirical data shows slight differences in efficacy; in particular, Cognitive Behavioural Therapy (CBT) yields small to medium sized effects in addition to psychopharmacological treatment.
There are several available manualized psychological group interventions for patients with a schizophrenic psychosis. One the is the "Integrated Psychological Therapy for Schizophrenia Patients (IPT)", it was developed and introduced into clinical practice almost 30 years ago. It combines neurocognitive and social cognitive interventions with social skills and problem- solving approaches, it has been extensively evaluated by several independent groups, in inpatient and outpatient settings as well, showing an overall improvement in participants.
During the last decade, the cognitive section of IPT was further developed, with the "Integrated Neurocognitive Therapy for schizophrenia patients (INT)" was the final result of this process, with the peculiarity that it was designed to fit the needs of outpatients. While IPT focuses predominantly on the domains of speed of processing, attention, reasoning, and problem-solving as well as on emotion and social perception; INT in contrast targets all 11 neuro- and social-cognitive MATRICS-domains. Furthermore, INT uses computerized neurocognitive exercises for restitution. Initial trials seem to confirm INT as a feasible and efficient group therapy approach with the potential to improve functional outcome in schizophrenia outpatients
The investigators, plan investigational trial to assess the efficacy and feasibility of INT for patients with schizophrenia in an inpatient setting. Therefore, an 8-week, randomized, controlled, assessor-blind, three-parallel-arm trial is planned with patients diagnosed with a schizophrenic psychosis. Following baseline assessment, patients will be randomly assigned to either IPT, INT or a control intervention.
All study interventions, i.e.: the experimental intervention, the psychological control intervention, and the control condition will occur simultaneously twice a week to avoid participants from involuntarily switch groups. Therapists of the psychological experimental and control intervention, as well as trainers involved in the control condition, are not involved in the recruitment, assessment, and assignment of participants of the study. Study interventions will be held in group sessions with 6 to 8 participants each; we plan to conduct five such batches till we reach our sample size of at least 30 participants in each intervention arm.
Patients undergoing psychological interventions should have some prerequisites and conditions which make them suitable for the intervention; this, however, is not fully compatible with a random allocation of participants. Through randomization there is the possibility that participants are not able to cope with their assigned treatment; therefore in a pragmatic way patients will be allowed to switch in another treatment arm. Accordingly after two weeks; patients will be reassessed; reallocation will be followed according to predefined criteria for excessive demands or under requirement.
Participants which switch groups should complete the 8-week intervention in the second assigned group. The assessment at week two will be considered their baseline, with subsequent measures eight weeks later analog to those who did not switch treatment groups. For the final analysis and to preserve randomization the data from those who did not switch treatment groups will be analyzed: however data from the switching groups will be analyzed separately in an ITT fashion.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- An 8-week, randomized, controlled, assessor-blind, three-parallel-arm trial is planned with patients diagnosed with a schizophrenic psychosis.
| Arm | Type | Receives |
|---|---|---|
| INT | Experimental | Behavioral: Integrated Neurocognitive Therapy (INT)Integrated Neurocognitive Therapy (INT) is a manualized psychological intervention that consists of 30 sessions administered by a therapist and a co-therapist in an open group of 6-8 patients. Sessions will take place twice a week, and each session should last 90 min. |
| IPT | Active comparator | Behavioral: Integrated Psychological Therapy (IPT)Integrated Psychological Therapy (IPT) is a manualized psychological intervention that consists of 5 modules which can be completed in a variable number of sessions that will be administered by a therapist and a co-therapist in an open group of 6- 8 patients. Sessions will take place twice a week, and each session should last 60 to 90 min. |
| CoC | Other | Other: COGPACKCOGPACK is a computer-based neuropsychological cognitive training program. It will be administered by a trainer in an open group of 6- 8 patients. Sessions will take place twice a week, and each session will last 45 - 60 minutes. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Participants are competent to give informed consent.
- Diagnosis of Schizophrenia or Schizoaffective Disorder (ICD-10).
- Participants are between 18 and 65 years of age.
- Fulfillment of regular compulsory education.
- German language proficiency as a native speaker or level B1
Key exclusion criteria (4 listed)
- Unwilling or unable to comply with study instructions.
- Low Intelligence as stated by failure to accomplish regular compulsory education.
- Currently in another psychotherapeutic treatment, either in individual or group sessions.
- Current consumption of Alcohol or illicit Drugs.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Integrated Neurocognitive Therapy (INT)Information already included in arm/group description. | Behavioural | INT |
| Integrated Psychological Therapy (IPT)Information already included in arm/group description. | Behavioural | IPT |
| COGPACKInformation already included in arm/group description. | Other | CoC |
Primary outcome
Change from Baseline Symptomatology at 12 Months.
Time frame: Baseline, 2 Weeks, 10 Weeks, 6 Months, and 12 Months.
The "Positive and Negative Syndrome Scale" (PANSS) was designed to measure the severity of psychopathology in adult patients with a psychotic disorder, mainly schizophrenia and schizoaffective disorder.
1 secondary outcome
Change from Baseline Symptomatology at 12 Months.
Time frame: Baseline, 2 Weeks, 10 Weeks, 6 Months, and 12 Months.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2021.
- Derived from this study: PubMed 32903368Redlich Bossy M, Mueller D, Seifritz E, Vetter S, Egger ST. Feasibility and Efficacy of a Psychological Therapy for Patients With a Schizophrenic Psychosis in an Inpatient Setting: Study Protocol of a Randomized Switch Controlled Trial. Front Public Health. 2020 Aug 12;8:391. doi: 10.3389/fpubh.2020.00391. eCollection 2020.
- Individual participant dataSharing planned: No
Related trials for Schizophrenia
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Deep Brain Stimulation for Treatment-Resistant Schizophrenia
Treatment Resistant Disorders
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Active, not recruiting
Designing and Evaluating a Classroom-Based Mental Health Programme for Adolescents.
Mental Health Promotion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Integrated Neurocognitive Therapy (INT), Integrated Psychological Therapy (IPT) and COGPACK in people with Schizophrenia and Schizoaffective Disorder, run by Psychiatric University Hospital, Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline Symptomatology at 12 Months. (time frame: Baseline, 2 Weeks, 10 Weeks, 6 Months, and 12 Months.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03316664, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2021.